These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 27009613)

  • 1. Passive immunization with HIV-1-neutralizing antibodies: is it effective and safe?
    Nittayananta W
    Oral Dis; 2016 Sep; 22(6):460-2. PubMed ID: 27009613
    [No Abstract]   [Full Text] [Related]  

  • 2. Model for competition from self during passive immunization, with application to broadly neutralizing antibodies for HIV.
    Ali Tabei SM; Li Y; Weigert M; Dinner AR
    Vaccine; 2012 Jan; 30(3):607-13. PubMed ID: 22119591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection.
    Stiegler G; Katinger H
    J Antimicrob Chemother; 2003 Apr; 51(4):757-9. PubMed ID: 12654737
    [No Abstract]   [Full Text] [Related]  

  • 4. HIV: Efficacy through BibNAbs.
    Flemming A
    Nat Rev Drug Discov; 2013 Sep; 12(9):666. PubMed ID: 23989794
    [No Abstract]   [Full Text] [Related]  

  • 5. In vivo protection by broadly neutralizing HIV antibodies.
    van Gils MJ; Sanders RW
    Trends Microbiol; 2014 Oct; 22(10):550-1. PubMed ID: 25169020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination antibody treatment controls HIV infection in phase 1 trial.
    Harper KN
    AIDS; 2019 Mar; 33(3):N3-N4. PubMed ID: 30585848
    [No Abstract]   [Full Text] [Related]  

  • 7. Prospects for passive immunity to prevent HIV infection.
    Morris L; Mkhize NN
    PLoS Med; 2017 Nov; 14(11):e1002436. PubMed ID: 29136030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short Communication: Exploring Antibody Potential as Prophylactic/Therapeutic Strategies for Prevention of Early Mucosal HIV-1 Infection.
    Su B; Peressin M; Ducloy C; Penichon J; Mayr LM; Laumond G; Schmidt S; Decoville T; Moog C
    AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1187-91. PubMed ID: 26252799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [HIV-1 cell-to-cell transmission and broadly neutralizing antibodies].
    Malbec M; Mouquet H; Schwartz O
    Med Sci (Paris); 2014 May; 30(5):508-10. PubMed ID: 24939535
    [No Abstract]   [Full Text] [Related]  

  • 10. Neutralizing antibodies take a swipe at HIV in vivo.
    Montefiori DC
    Nat Med; 2005 Jun; 11(6):593-4. PubMed ID: 15937465
    [No Abstract]   [Full Text] [Related]  

  • 11. Passive immunization with human neutralizing monoclonal antibodies against HIV-1 in macaque models: experimental approaches.
    Ruprecht RM
    Methods Mol Biol; 2009; 525():559-66, xiv. PubMed ID: 19252837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Broadly Neutralizing Antibodies for HIV Eradication.
    Stephenson KE; Barouch DH
    Curr HIV/AIDS Rep; 2016 Feb; 13(1):31-7. PubMed ID: 26841901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PUBLIC HEALTH. Toward an HIV vaccine: A scientific journey.
    Fauci AS; Marston HD
    Science; 2015 Jul; 349(6246):386-7. PubMed ID: 26206922
    [No Abstract]   [Full Text] [Related]  

  • 14. Inhibition of replication of primary HIV-1 isolates in huPBL-NOD/Scid mice by antibodies from HIV-1 infected patients.
    Steyaert S; Heyndrickx L; Verhoye L; Vermoesen T; Donners H; Fransen K; Van Wanzeele F; Vandergucht B; Vanham G; Leroux-Roels G; Vanlandschoot P
    Antiviral Res; 2007 Aug; 75(2):129-38. PubMed ID: 17379323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.
    Trkola A; Kuster H; Rusert P; Joos B; Fischer M; Leemann C; Manrique A; Huber M; Rehr M; Oxenius A; Weber R; Stiegler G; Vcelar B; Katinger H; Aceto L; Günthard HF
    Nat Med; 2005 Jun; 11(6):615-22. PubMed ID: 15880120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human monoclonal antibodies for passive immunotherapy of HIV-1.
    Katinger H
    Antibiot Chemother (1971); 1994; 46():25-37. PubMed ID: 7826037
    [No Abstract]   [Full Text] [Related]  

  • 17. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
    Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
    Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broadly neutralizing antibodies against HIV-1: templates for a vaccine.
    van Gils MJ; Sanders RW
    Virology; 2013 Jan; 435(1):46-56. PubMed ID: 23217615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vector-mediated antibody gene transfer for infectious diseases.
    Schnepp BC; Johnson PR
    Adv Exp Med Biol; 2015; 848():149-67. PubMed ID: 25757620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.
    Sadanand S; Suscovich TJ; Alter G
    Annu Rev Med; 2016; 67():185-200. PubMed ID: 26565674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.